Latest:
Dr. Raz on the Effects of COVID-19 on Lung Cancer Screening
Dan J. Raz, MAS, MD, discusses the effects of COVID-19 on lung cancer screening.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Dana Chase, MD
Dana Chase, MD, is an associate professor of obstetrics and gynecology in the Division of Gynecologic Oncology at UCLA Health.
Latest:
Unmet Needs and Future Research Focus for Endometrial Cancer
Panelists discuss how addressing molecular, clinical, and access-related gaps remains essential for advancing endometrial cancer research and care.
Dana E. Rathkopf, MD
Dana E. Rathkopf, MD, is a genitourinary medical oncologist and chair of the Research Council at Memorial Sloan Kettering Cancer Center in New York.
Latest:
Dr Rathkopf on the Rationale for Evaluating Niraparib Plus Abiraterone Acetate in HRR+ mCSPC
Dana E. Rathkopf, MD, discusses the purpose of evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.
Dana M. Chase, MD, FACOG
Latest:
Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents
Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.
Danelle James, MD, MAS
Latest:
Dr. James on Update of Ibrutinib for Chronic Lymphocytic Leukemia
Danelle James, MD, MAS, head of Oncology at Pharmacyclics, assistant adjunct professor in the Division of Hematology-Oncology at the Chronic Lymphocytic Leukemia Research Consortium, discusses the RESONATE-2 study of ibrutinib (Imbruvica) versus chlorambucil through 5 years of treatment.
Daneng Li, MD
Daneng Li, MD, is an associate professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Neuroendocrine Tumor Program at City of Hope.
Latest:
AE Management of Cabozantinib
Panelists discuss how managing cabozantinib’s adverse effects requires proactive patient counseling about expected dose reductions, aggressive supportive care for manageable toxicities like hypertension and diarrhea, frequent early monitoring, and recognition that the median effective dose (40 mg) is lower than the starting dose (60 mg).
Daniel A. Hamstra, MD, PhD
Latest:
Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate Cancer
Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.
Daniel B. Costa, MD, PhD, MMSc
Latest:
Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC
Daniel B. Costa, MD, PhD, MMSc, associate professor of medicine at Harvard Medical School, medical staff, Hematology/Oncology, medical director of the Cancer Clinical Trials Office, and Medical Center Thoracic Oncology Group Leader, of Beth Israel Deaconess Medical Center, discusses biomarkers beyond PD-L1 in development for immunotherapy in patients with non–small cell lung cancer (NSCLC).